Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

atigue. At week 24, the mean improvement in FACIT-F was 7.2 +/- 8.6 in the combined golimumab group, compared with an improvement of 2.2 +/- 9.5 among patients receiving methotrexate alone (P < 0.001).

According to the Arthritis Foundation, in addition to joint pain and swelling, RA may make daily functioning difficult and is frequently associated with fatigue. "Patients with RA often say that fatigue is one of their most frustrating symptoms because it makes it difficult for them to participate in work or social activities," said Mark Genovese, M.D., professor of medicine at Stanford University School of Medicine, and lead study investigator. "A reduction in fatigue would represent a tremendous benefit and significantly impact the lives of patients with this disease."

Through week 24, patients in both dose groups receiving golimumab plus methotrexate experienced significant improvement in physical function, compared with patients receiving methotrexate alone. At 24 weeks, 70 percent of those receiving golimumab plus methotrexate experienced a clinically relevant improvement in physical function, compared with 39 percent of patients receiving methotrexate alone (P < 0.0001). Also at week 24, the combined golimumab group achieved a mean improvement in HAQ of 0.46 +/- 0.53, compared with an improvement of 0.13 +/- 0.58 among patients receiving methotrexate alone (P < 0.001).

Patients treated with golimumab also experienced significant improvement in HRQOL, as assessed by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the Short form (SF)-36 questionnaire. In the combined golimumab plus methotrexate group, the mean improvement in PCS at week 14 was 7.7 +/- 8.1, compared with an improvement of 2.5 +/- 8.1 in the group receiving methotrexate alone (P < 0.001). Patients in the combined group also experienced a mean improvement in MCS of 3.1 +/- 10.8 at week 24, compared with 0.8 +/- 9.7 among patients receiving methot
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Cerimon Pharmaceuticals, Inc., announced today the ... topical diclofenac sodium patch Phase III program. The ... clinical studies with Cerimon,s diclofenac patch. The studies ... patch compared to placebo for the treatment of acute ...
... Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the life saving ... internationally, today announced an agreement with Shelter Island ... restructuring is a major step forward for Cord ...
... growers are looking for "the sweet spot" - the ideal combination ... of the North Central Soybean Research Program offers suggestions to help ... ... Urbandale, Iowa (PRWEB) February 25, 2009 -- Optimal soybean ...
Cached Biology Technology:Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Cord Blood America Restructures Debt; Projects to be Cash Flow Positive 2NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 2NCSRP Research Director: "Earlier Planting can Increase Soybean Yields" 3
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
(Date:7/9/2014)... RIVERSIDE, Calif. Jason Stajich , an associate ... the University of California, Riverside, has been awarded the ... of America, a scientific society dedicated to advancing the ... all kinds including mushrooms, molds, truffles, yeasts, lichens, plant ... peer-nominated and each year recognizes an outstanding early-career mycologist. ...
(Date:7/9/2014)... which animals can be found, concern mounts over the ... range for a host mean new territory for its ... of UC Santa Barbara scientists, including parasitologists Ryan Hechinger ... Journal of Biogeography , Hechinger, Kuris and colleagues ... Hosts may actually lose their parasites when the hosts ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2Not at home on the range 2Not at home on the range 3Not at home on the range 4
... the University of Verona and the Institute G. Gaslini ... Cytomegalovirus infection in the pathogenesis of atherosclerosis. , Atherosclerosis ... Classic risk factors including smoking, diabetes, hypertension and high ... in the pathogenesis of the disease that also recognises ...
... emergency rooms to treat methamphetamine overdose damages nerve cells ... movement, a new study shows. , The findings, derived ... of the medication, haloperidol, and methamphetamine causes the destructive ... PhD, and his team at Boston University School of ...
... deer are giving new meaning to watching out for other ... and whitetail deer conducted by the University of Alberta in ... showed that both species responded to the recorded distress calls ... fawns, with mule deer mothers responding to both whitetail and ...
Cached Biology News:Cytomegalovirus exacerbates atherosclerosis through an autoimmune mechanism 2Common treatment for methamphetamine overdose may damage brain cells 2Mule deer moms rescue other fawns 2
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
... Detection of the yolk protein Vtg in ... simple and sensitive biomarker for endocrine disrupting chemicals ... Vtg has become an accepted screening test for ... Vtg (rainbow trout) EIA kit is a double-antibody ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
... whose sequence is from rat SCAMP 5. The sequence of ... - Q - P - Q - T - Q - ... - Y - T - Y - S - N(233). ... with the polyclonal antibody that reacts with this product and the ...
Biology Products: